Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
UBS
Covington
Moodys
Queensland Health
Citi
Medtronic
Mallinckrodt

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,943,166

« Back to Dashboard

Which drugs does patent 6,943,166 protect, and when does it expire?

Patent 6,943,166 protects CIALIS and is included in one NDA.

Protection for CIALIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-seven patent family members in forty-seven countries.
Summary for Patent: 6,943,166
Title: Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Abstract:The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
Inventor(s): Pullman; William Ernest (Far Hills, NJ), Whitaker; John Steven (Woodinville, WA)
Assignee: Lilly ICOS LLC. (Wilmington, DE)
Application Number:10/031,556
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,943,166
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,943,166

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly CIALIS tadalafil TABLET;ORAL 021368-004 Jan 7, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly CIALIS tadalafil TABLET;ORAL 021368-001 Nov 21, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly CIALIS tadalafil TABLET;ORAL 021368-002 Nov 21, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,943,166

PCT Information
PCT FiledApril 26, 2000PCT Application Number:PCT/US00/11129
PCT Publication Date:November 09, 2000PCT Publication Number: WO00/66099

Non-Orange Book US Patents Family Members for Patent 6,943,166

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,807 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Moodys
QuintilesIMS
Boehringer Ingelheim
Cipla
Harvard Business School
McKinsey
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.